<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01451853</url>
  </required_header>
  <id_info>
    <org_study_id>SPI-3005-201</org_study_id>
    <nct_id>NCT01451853</nct_id>
  </id_info>
  <brief_title>SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss</brief_title>
  <official_title>Safety and Efficacy Study of SPI-1005 for Prevention of Chemotherapy Induced Hearing Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sound Pharmaceuticals, Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VA Puget Sound Health Care System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Sound Pharmaceuticals, Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chemotherapy treatment with platinum based agents is well noted to cause ototoxicity. It is
      the objective of this study to determine the safety and efficacy of SPI-1005 at three dose
      levels when delivered orally twice daily for 3 days, surrounding each cycle of platinum
      chemotherapy in head and neck or non-small cell lung cancer patients to prevent and treat
      chemotherapy induced hearing loss and tinnitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chemotherapy treatment with the platinum containing chemotherapies (e.g. cisplatin,
      carboplatin) are well noted and studied for their ability to cause ototoxicity which includes
      hearing loss, tinnitus, vertigo, or dizziness. It is the objective of this study to determine
      the safety and efficacy of SPI-1005 at three dose levels when delivered orally twice daily
      for 3 days, surrounding each cycle of platinum chemotherapy for head and neck or non-small
      cell lung cancer patients to prevent and treat chemotherapy induced hearing loss and
      tinnitus.

      SPI-1005, a proprietary oral formulation of ebselen is a small molecule mimic and inducer of
      the enzyme Glutathione Peroxidase. GPx reduces reactive oxygen species (ROS) by reacting with
      glutathione. SPI-1005 has been shown to reduce cisplatin induced hearing threshold shift in
      animal studies.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 15, 2018</start_date>
  <completion_date type="Anticipated">September 23, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 26, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of hearing loss incidence and severity</measure>
    <time_frame>From baseline through 1 month after last chemotherapy cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of tinnitus incidence and severity.</measure>
    <time_frame>From baseline through 1 month after last chemotherapy cycle</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Hearing Loss</condition>
  <condition>Ototoxicity</condition>
  <condition>Tinnitus</condition>
  <condition>Neuropathy</condition>
  <arm_group>
    <arm_group_label>SPI-1005 Low Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200 mg SPI-1005, capsule, po, bid, x3d surrounding each cycle of chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPI-1005 Middle Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>400 mg SPI-1005, capsule, po, bid, x3d surrounding each cycle of chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPI-1005 High Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>600 mg SPI-1005, capsule, po, bid, x3d surrounding each cycle of chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0 mg SPI-1005, capsule, po, bid, x3d surrounding each cycle of chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPI-1005 Low Dose</intervention_name>
    <description>Oral capsules, 200 mg ebselen, twice daily, 3 days for each cycle of chemotherapy
Arms: Low Dose
Other Names:
200 mg Ebselen</description>
    <arm_group_label>SPI-1005 Low Dose</arm_group_label>
    <other_name>200 mg Ebselen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPI-1005 Middle Dose</intervention_name>
    <description>Oral capsules, 400 mg ebselen, twice daily, 3 days for each cycle of chemotherapy</description>
    <arm_group_label>SPI-1005 Middle Dose</arm_group_label>
    <other_name>400 mg Ebselen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPI-1005 High Dose</intervention_name>
    <description>Oral capsules, 600 mg ebselen, twice daily, 3 days for each cycle of chemotherapy</description>
    <arm_group_label>SPI-1005 High Dose</arm_group_label>
    <other_name>600 mg Ebselen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral capsules, 0 mg ebselen, twice daily, 3 days for each cycle of chemotherapy</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>0 mg Ebselen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult male and female subjects, 19-80 years of age;

          -  Confirmed diagnosis of advanced head and neck cancer or advanced lung cancer

          -  Voluntarily consent to participate in the study

          -  Females of childbearing potential should either be sexually inactive (abstinent) for
             14 days prior to screening and throughout the study or be using one of the following
             acceptable birth control methods:

          -  IUD in place for at least 3 months prior to study;

          -  Barrier method (condom or diaphragm) with spermicide for at least 14 days prior to
             screening through study completion;

          -  Stable hormonal contraceptive for at least 3 months prior to study through completion
             of study;

          -  Surgical sterilization (vasectomy) of partner at least 6 months prior to study.

          -  Females of non-childbearing potential should be surgically sterile (bilateral tubal
             ligation with surgery at least 6 months prior to study, hysterectomy, or bilateral
             oophorectomy at least 2 months prior to study).

        Exclusion Criteria:

          -  Subjects previously treated with chemotherapy, antibiotics, or diuretics known to
             cause hearing loss in the last 90 days

          -  History or presence of significant cardiovascular, pulmonary, hepatic, renal,
             hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic,
             otologic, or psychiatric disease

          -  Presence of alcoholism or drug abuse

          -  Participation in another investigational drug or device clinical trial within 30 days
             prior to the study

          -  Female subjects who are pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Kil, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sound Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric Lynch, PhD</last_name>
    <phone>(206) 634-2559</phone>
    <email>elynch@soundpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>VA Puget Sound Health Care</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tony S. Quang, M.D.</last_name>
      <phone>206-768-5356</phone>
    </contact>
    <investigator>
      <last_name>Tony S Quang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Rybak LP, Whitworth C, Somani S. Application of antioxidants and other agents to prevent cisplatin ototoxicity. Laryngoscope. 1999 Nov;109(11):1740-4.</citation>
    <PMID>10569399</PMID>
  </reference>
  <reference>
    <citation>Rybak LP, Somani S. Ototoxicity. Amelioration by protective agents. Ann N Y Acad Sci. 1999 Nov 28;884:143-51.</citation>
    <PMID>10842591</PMID>
  </reference>
  <reference>
    <citation>Lynch ED, Gu R, Pierce C, Kil J. Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen. Hear Res. 2005 Mar;201(1-2):81-9.</citation>
    <PMID>15721563</PMID>
  </reference>
  <reference>
    <citation>Lynch ED, Gu R, Pierce C, Kil J. Combined oral delivery of ebselen and allopurinol reduces multiple cisplatin toxicities in rat breast and ovarian cancer models while enhancing anti-tumor activity. Anticancer Drugs. 2005 Jun;16(5):569-79.</citation>
    <PMID>15846123</PMID>
  </reference>
  <reference>
    <citation>Knight KR, Kraemer DF, Winter C, Neuwelt EA. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol. 2007 Apr 1;25(10):1190-5.</citation>
    <PMID>17401008</PMID>
  </reference>
  <reference>
    <citation>Reavis KM, Phillips DS, Fausti SA, Gordon JS, Helt WJ, Wilmington D, Bratt GW, Konrad-Martin D. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss. Ear Hear. 2008 Dec;29(6):875-93. doi: 10.1097/AUD.0b013e318181ad99.</citation>
    <PMID>18753950</PMID>
  </reference>
  <reference>
    <citation>Kim SJ, Park C, Han AL, Youn MJ, Lee JH, Kim Y, Kim ES, Kim HJ, Kim JK, Lee HK, Chung SY, So H, Park R. Ebselen attenuates cisplatin-induced ROS generation through Nrf2 activation in auditory cells. Hear Res. 2009 May;251(1-2):70-82. doi: 10.1016/j.heares.2009.03.003. Epub 2009 Mar 13.</citation>
    <PMID>19286452</PMID>
  </reference>
  <reference>
    <citation>Lynch E, Kil J. Development of Ebselen, a Glutathione Peroxidase Mimic, for the Prevention and Treatment of Noise-Induced Hearing Loss. Semin Hear 2009; 30(1): 047-055</citation>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2011</study_first_submitted>
  <study_first_submitted_qc>October 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2011</study_first_posted>
  <last_update_submitted>September 21, 2017</last_update_submitted>
  <last_update_submitted_qc>September 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung Cancer</keyword>
  <keyword>Head and Neck Cancer</keyword>
  <keyword>Hearing Loss</keyword>
  <keyword>Ototoxicity</keyword>
  <keyword>Tinnitus</keyword>
  <keyword>Deafness</keyword>
  <keyword>SPI-1005</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Ebselen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Hearing Loss</mesh_term>
    <mesh_term>Deafness</mesh_term>
    <mesh_term>Tinnitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ebselen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

